信必可都保联合异丙托溴铵雾化吸入对COPD患者炎性因子水平及肺功能的影响  

Effects of Chembecorturbo combined with ipratropium bromide aerosol inhalation on inflammatory factors and lung function in patients with COPD

作　　者：钟蕾 张佩 Zhong Lei;Zhang Pei(Department of Pharmacy,People's Hospital of Shangli County,Shangli County,Jiangxi Province 337009;Department of Pharmacy,Shangrao Central Hospital,Shangrao 334000,China)

机构地区：[1]上栗县人民医院药剂科,江西上栗337009 [2]上饶市中心医院药剂科,江西上饶334000

出　　处：《青岛医药卫生》2024年第4期261-264,共4页Qingdao Medical Journal

基　　金：萍乡市科技计划项目(编号:2021PY265)。

摘　　要：目的探讨信必可都保联合异丙托溴铵雾化吸入对慢性阻塞性肺疾病(COPD)患者炎性因子水平及肺功能的影响。方法选取医院2023年1月~2024年1月收治的95例COPD患者,以抽签法分为对照组(48例)、治疗组(47例)。对照组予异丙托溴铵雾化吸入治疗,治疗组予信必可都保联合异丙托溴铵雾化吸入治疗;对比两组治疗效果、炎性因子水平(C反应蛋白(CRP)、降钙素原(PCT)、白细胞介素6(IL-6))、血气指标(动脉血二氧化碳分压(PaCO_(2))、动脉血氧分压(PaO_(2)))、肺功能指标[用力肺活量(FVC)、呼气峰值流速(PEF)及第1s用力呼气容积(FEV1)]及不良反应。结果治疗组总有效率(93.62%)较对照组(75.00%)高,差异有统计学意义(P<0.05);治疗2周后,治疗组CRP(10.51±2.35)mg/L、PCT(0.10±0.02)ng/Lng/ml、IL-6(112.25±16.35)、PaCO_(2)(38.65±3.14)mmHg水平较对照组(15.24±3.42)mg/L、(0.16±0.05)ng/ml、(130.24±18.41)ng/L、(44.58±3.60)mmHg低,PaO_(2)(80.24±6.85)mmHg、FVC(3.11±0.48)L、PEF(3.22±0.81)L/s及FEV1(2.62±0.48)L水平较对照组(72.54±6.33)mmHg、(2.89±0.40)L、(2.81±0.74)L/s、(2.31±0.41)L高,差异有统计学意义(P<0.05);治疗组(14.89%)与对照组不良反应(10.42%)对比,差异无统计学意义(P>0.05)。结论COPD患者采用信必可都保联合异丙托溴铵雾化吸入治疗效果较好,利于减轻炎性反应,改善血气状况,提升肺功能,且安全性好。Objective To investigate the effects of Symbicor Turbot combined with ipratropium bromide aerosol inhalation on inflammatory factors and lung function in patients with chronic obstructive pulmonary disease(COPD).Methods A total of 95 COPD patients admitted to the hospital from January 2023 to January 2024 were divided into control group(48 cases)and treatment group(47 cases)by drawing lots.The control group was given atomized inhalation of ipratropium bromide,the treatment group was treated with Cymbicort Dupro combined with ipratropium bromide nebulized inhalation therapy.The therapeutic effect,inflammatory factor levels[C-reactive protein(CRP),procalcitonin(PCT),interleukin-6(IL-6)],blood gas indexes[arterial partial pressure of carbon dioxide(PaCO_(2)),arterial partial pressure of oxygen(PaO_(2))],pulmonary function indexes[forced vital capacity(FVC),peak expiratory flow rate(PEF)and 1s usage were compared between the two groups Force expiratory volume(FEV1)]and adverse reactions.Results The total effective rate of the treatment group(93.62%)was higher than that of the control group(75.00%),the difference was statistically significant(P<0.05).After two weeks of treatment,The levels of CRP(10.51±2.35)mg/L,PCT(0.10±0.02)ng/Lng/ml,IL-6(112.25±16.35),PaCO_(2)(38.65±3.14)mmHg in the treatment group were higher than those in the control group(15.24±3.42)mg/L,(0.16±0.05))ng/ml,(130.24±18.41)ng/L,(44.58±3.60)mmHg low,The levels of PaO_(2)(80.24±6.85)mmHg,FVC(3.11±0.48)L,PEF(3.22±0.81)L/s and FEV1(2.62±0.48)L/s were higher than those of the control group(72.54±6.33)mmHg,(2.89±0.40)L and(2.81±0.74)L/s s and(2.31±0.41)L were high,and the difference was statistically significant(P<0.05).There was no significant difference in adverse reactions between the treatment group(14.89%)and the control group(10.42%)(P>0.05).Conclusion The treatment of COPD patients with Symbicor Turbot combined with ipratropium bromide is effective,which is beneficial to reduce inflammatory response,improve blood gas status,and enha

关 键 词：慢性阻塞性肺疾病 信必可都保 异丙托溴铵 雾化吸入 炎性因子 肺功能 

分 类 号：R563[医药卫生—呼吸系统]